Structures by: Sridhar B.
Total: 368
2,3,3a,4,5,9b-hexahydro-4-phenylfuro[3,2-c]quinoline
C17H17NO
Acta Crystallographica Section E (2006) 62, 2 o542-o544
a=9.3760(6)Å b=9.9065(6)Å c=16.0140(10)Å
α=96.9540(10)° β=102.0050(10)° γ=110.6930(10)°
[(1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthy]methylammonium chloride
C17H18Cl2N,Cl
Acta Crystallographica Section E (2006) 62, 2 o565-o567
a=7.289(6)Å b=7.396(7)Å c=32.66(3)Å
α=90.00° β=90.00° γ=90.00°
Sumatriptan
C14H21N3O2S
Acta Crystallographica Section E (2006) 62, 3 o1086-o1088
a=6.3216(3)Å b=10.1290(5)Å c=24.1541(12)Å
α=90.00° β=96.3180(10)° γ=90.00°
6-[(Dimethylamino)methyleneamino]-1,3-dimethylpyrimidine-2,4(1H,3H)-dione dihydrate
C9H14N4O2,2(H2O)
Acta Crystallographica Section E (2008) 64, 9 o1662
a=7.1310(5)Å b=9.8571(7)Å c=9.9160(7)Å
α=92.9210(10)° β=101.9160(10)° γ=109.9120(10)°
3-(2-chloroethyl)-2-methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin- 1-ium chloride
C11H16ClN2O,Cl
Acta Crystallographica Section E (2006) 62, 9 o3730-o3731
a=6.609(5)Å b=10.340(8)Å c=18.473(14)Å
α=90.00° β=90.00° γ=90.00°
(3Z)-2-Benzyl-3-benzylidene-6-phenyl-2-azabicyclo[2.2.2]octan-5-one
C27H25NO
Acta Crystallographica Section E (2007) 63, 3 o1500-o1501
a=9.5155(7)Å b=17.6544(13)Å c=12.4242(9)Å
α=90.00° β=97.4640(10)° γ=90.00°
Meso-1,2-Diphenylethylenediammonium bis(hydrogen squarate)
C14H18N22,2C4HO4
Acta Crystallographica Section E (2007) 63, 6 o3034-o3035
a=6.3817(6)Å b=7.3925(7)Å c=11.5034(11)Å
α=86.765(2)° β=80.552(2)° γ=68.4200(10)°
3-[4-(Dimethylamino)benzylideneamino]-2-methylquinazolin-4(3H)-one
C18H18N4O
Acta Crystallographica Section E (2007) 63, 11 o4293-o4293
a=7.5175(10)Å b=9.3631(13)Å c=12.7886(17)Å
α=98.198(2)° β=103.259(2)° γ=112.517(2)°
4-Benzylidene-2-methyl-11-phenyl-1,2,3,4,11,11a-hexahydropyrido[3,4-<i>c</i>][1,5]benzothiazepine
C26H24N2S
Acta Crystallographica Section E (2007) 63, 11 o4359-o4360
a=11.7545(6)Å b=15.5571(7)Å c=12.1496(6)Å
α=90.00° β=106.1140(10)° γ=90.00°
Tetraaqua(2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylato- κ^2^N^3^,O)cobalt(II) 2.5-hydrate
C5H10CoN2O8,2.5(H2O)
Acta Crystallographica Section E (2007) 63, 12 m2887-m2888
a=20.8700(19)Å b=17.1153(16)Å c=7.3375(7)Å
α=90.00° β=90.00° γ=90.00°
5-(2-Methyl-2-nitro-1-phenylpropyl)-4-phenyl-1,2,3-selenadiazole
C18H17N3O2Se
Acta Crystallographica Section E (2007) 63, 12 o4676-o4676
a=10.0178(8)Å b=10.2084(8)Å c=17.4139(14)Å
α=90.00° β=104.8200(10)° γ=90.00°
8-Ethoxy-3-(4-isopropylbenzylidene)-6-methylchroman-4-one
C22H24O3
Acta Crystallographica Section E (2008) 64, 1 o328-o328
a=10.3568(9)Å b=16.8154(15)Å c=10.8962(10)Å
α=90.00° β=99.8730(10)° γ=90.00°
1-Vinyl-1H-indole-3-carbaldehyde
C11H9NO
Acta Crystallographica Section E (2008) 64, 6 o1163
a=8.3200(5)Å b=8.1490(5)Å c=13.1620(7)Å
α=90.00° β=99.9520(10)° γ=90.00°
1-[4-oxo-4-(2,4,6-trimethoxy­phenyl)but-1-yl]pyrrolidinium hydrochloride
C17H26NO4,Cl
Acta Crystallographica Section E (2006) 62, 11 o4832-o4834
a=7.0333(5)Å b=29.534(2)Å c=9.1257(6)Å
α=90.00° β=104.7570(10)° γ=90.00°
Dimethyl 2,6-dimethyl-4-[4-(benzoyloxy)phenyl]-1,4-dihydropyridine-3,5-dicarboxylate
C24H23NO6
Acta Crystallographica Section E (2006) 62, 9 o3701-o3703
a=7.8943(6)Å b=10.6426(8)Å c=25.7386(18)Å
α=90.00° β=94.6420(10)° γ=90.00°
1-[5-(4-Fluorophenyl)-1,2-oxazol-3-ylmethyl]-2-nitroiminoimidazolidine
C13H12FN5O3
Acta Crystallographica Section E (2006) 62, 9 o3850-o3851
a=7.8575(6)Å b=15.6860(12)Å c=11.4098(9)Å
α=90.00° β=107.9450(10)° γ=90.00°
Dimethyl 4-(4-isopropylcarbonyloxyphenyl)-2,6-dimethyl- 1,4-dihydropyridine-3,5-dicarboxylate
C21H25NO6
Acta Crystallographica Section E (2006) 62, 9 o4001-o4003
a=8.4488(4)Å b=10.5809(5)Å c=11.5520(6)Å
α=103.0200(10)° β=95.9710(10)° γ=95.5060(10)°
Lamotrigine dimethylformamide sesquisolvate
C9H7Cl2N5,1.5C3H7NO
Acta Crystallographica Section E (2006) 62, 10 o4752-o4754
a=10.4444(13)Å b=10.9943(13)Å c=16.976(2)Å
α=83.637(2)° β=74.850(2)° γ=70.582(2)°
Palonosetron hydrochloride
C19H25ON2,Cl
Acta Crystallographica Section E (2007) 63, 3 o1404-o1406
a=7.4972(7)Å b=9.0288(8)Å c=25.045(2)Å
α=90.00° β=90.00° γ=90.00°
4-(2,4-Dichlorophenyl)-5-(N,N-diethylcarbamoyl)-6-methyl-3,4-dihydropyrimidine- 2(1H)-thione
C16H19Cl2N3OS
Acta Crystallographica Section E (2007) 63, 4 o1772-o1773
a=11.7548(11)Å b=14.4443(14)Å c=20.946(2)Å
α=90.00° β=90.00° γ=90.00°
Rizatriptan benzoate
C15H20N5,C7H5O2
Acta Crystallographica Section E (2007) 63, 4 o1958-o1960
a=8.7405(6)Å b=21.3242(15)Å c=22.2434(16)Å
α=90.00° β=90.00° γ=90.00°
Creatininium benzoate
C4H8N3O,C7H5O2
Acta Crystallographica Section E (2007) 63, 4 o1714-o1716
a=8.5574(5)Å b=6.2094(4)Å c=22.0169(14)Å
α=90.00° β=99.9040(10)° γ=90.00°
Zolmitriptan
C16H21N3O2
Acta Crystallographica Section E (2007) 63, 4 o1774-o1776
a=9.0643(7)Å b=11.4220(9)Å c=14.6320(12)Å
α=90.00° β=90.00° γ=90.00°
Zolmitriptan.chloroform
C16H21N3O2,CHCl3
Acta Crystallographica Section E (2007) 63, 4 o1961-o1962
a=7.9987(6)Å b=12.8279(9)Å c=20.2396(14)Å
α=90.00° β=90.00° γ=90.00°
Creatininium hydrogen oxalate monohydrate
C4H8N3O,C2HO4,H2O
Acta Crystallographica Section E (2007) 63, 6 o2387-o2389
a=9.1728(7)Å b=6.3520(5)Å c=16.6567(12)Å
α=90.00° β=90.00° γ=90.00°
(2S)-2-Benzyl-1-[(4R)-4-benzyl-2,2-dimethyl-1,3-oxazolan-3-yl]pent-4-en-1-one
C24H29NO2
Acta Crystallographica Section E (2006) 62, 10 o4755-o4757
a=10.0061(12)Å b=11.5146(14)Å c=18.602(2)Å
α=90.00° β=90.00° γ=90.00°
Voriconazole
C16H14F3N5O
Acta Crystallographica Section E (2007) 63, 2 o565-o567
a=7.5332(19)Å b=8.349(2)Å c=12.989(3)Å
α=90.00° β=100.062(4)° γ=90.00°
2-carboxyanilinium nitrate
C7H8NO2,NO3
Acta Crystallographica Section E (2007) 63, 5 o2722-o2723
a=12.2368(7)Å b=5.0082(3)Å c=14.8395(9)Å
α=90.00° β=108.2700(10)° γ=90.00°
Erlotinib hydrochloride
C22H24N3O4,Cl
Acta Crystallographica Section E (2008) 64, 5 o931
a=14.5351(15)Å b=18.4863(19)Å c=8.1222(8)Å
α=90.00° β=102.966(2)° γ=90.00°
Donepezilium oxalate trihydrate
C24H30NO3,C2HO4,3H2O
Acta Crystallographica Section C (2006) 62, 12 o681-o683
a=8.5002(5)Å b=17.6318(10)Å c=18.2158(10)Å
α=90.00° β=97.7440(10)° γ=90.00°
(2Z)-2-benzylidene-N,7-dimethyl-3-oxo-5-phenyl- 5H-1,3-thiazolo[3,2-a]pyrimidine-6(3H)-carboxamide
C22H19N3O2S
Acta Crystallographica Section C (2006) 62, 12 o687-o690
a=9.5353(6)Å b=10.2071(6)Å c=20.7901(12)Å
α=79.1980(10)° β=79.6450(10)° γ=78.2570(10)°
(2Z)-2-benzylidene-N,7-dimethyl-3-oxo-5-phenyl- 5H-1,3-thiazolo[3,2-a]pyrimidine-6(3H)-carboxamide
C22H19N3O2S
Acta Crystallographica Section C (2006) 62, 12 o687-o690
a=5.1109(9)Å b=9.5564(16)Å c=20.503(3)Å
α=97.594(3)° β=93.371(3)° γ=101.755(3)°
Lenalidomide
C13H13N3O3
Acta Crystallographica Section C (2009) 65, 10 o502-o505
a=5.9983(5)Å b=8.9198(8)Å c=11.5785(10)Å
α=75.7110(10)° β=84.6600(10)° γ=86.0380(10)°
Lenalidomide hemihydrate
C13H13N3O3,0.5H2O
Acta Crystallographica Section C (2009) 65, 10 o502-o505
a=8.4425(7)Å b=22.2874(19)Å c=13.6627(12)Å
α=90.00° β=101.0690(10)° γ=90.00°
Methyl 2-{3-[(<i>tert</i>-butoxycarbonyl)amino]-1-methyl-2-oxoindolin-3-yl}-2-methoxy-2-phenylacetate
C24H28N2O6
Acta Crystallographica Section C (2015) 71, 4 322-329
a=16.7030(13)Å b=8.0515(6)Å c=17.0919(13)Å
α=90° β=90° γ=90°
Methyl 2-{3-[(<i>tert</i>-butoxycarbonyl)amino]-1-methyl-2-oxoindolin-3-yl}-2-[(4-methoxybenzyl)oxy]-2-phenylacetate
C31H34N2O7
Acta Crystallographica Section C (2015) 71, 4 322-329
a=13.9402(12)Å b=16.5380(15)Å c=14.3279(13)Å
α=90° β=116.0420(10)° γ=90°
Methyl 2-[(anthracen-9-yl)methoxy]-2-{3-[(<i>tert</i>-butoxycarbonyl)amino]-1-methyl-2-oxoindolin-3-yl}-2-phenylacetate
C38H36N2O6
Acta Crystallographica Section C (2015) 71, 4 322-329
a=18.2606(17)Å b=9.8976(9)Å c=18.5364(17)Å
α=90° β=99.310(2)° γ=90°
Bis(adeninium) phthalate phthalic acid 1.45-hydrate
2C5H6N5,C8H4O42,C8H6O4,1.45H2O
Acta Crystallographica Section C (2007) 63, 4 o212-o214
a=7.0100(5)Å b=33.052(2)Å c=24.2496(17)Å
α=90.00° β=90.00° γ=90.00°
6,8-dinitro-2,4-dihydro-1<i>H</i>- benzo[<i>b</i>][1,2,4]triazolo[4,3-<i>d</i>][1,4]oxazin-1-one
C9H5N5O6
Acta Crystallographica Section C (2012) 68, 8 o302-o307
a=6.6313(4)Å b=18.5174(11)Å c=8.3354(5)Å
α=90.00° β=91.3520(10)° γ=90.00°
(<i>E</i>)-2-(2-hydroxy-4-oxopent-2-en-3-yl)-6,8-dinitro-2,4-dihydro- 1<i>H</i>-benzo[<i>b</i>][1,2,4]triazolo[4,3-<i>d</i>][1,4]oxazin-1-one
C14H11N5O8
Acta Crystallographica Section C (2012) 68, 8 o302-o307
a=7.2636(8)Å b=17.673(2)Å c=12.0447(13)Å
α=90.00° β=90.00° γ=90.00°
Cytosine
C4H5N3O
Acta Crystallographica Section C (2015) 71, 2
a=15.1040(10)Å b=15.1212(10)Å c=9.2948(6)Å
α=90° β=90° γ=90°
Adeninium hemioxalate chloride
2(C5H7N52),C2O42,2(Cl)
Acta Crystallographica Section C (2009) 65, 5 o202-o206
a=4.3758(4)Å b=17.1354(15)Å c=11.1188(10)Å
α=90.00° β=96.558(2)° γ=90.00°
Adeninium oxalate hemioxalic acid hydrate
C5H6N5,C2HO4,0.5C2H2O4,H2O
Acta Crystallographica Section C (2009) 65, 5 o202-o206
a=3.6222(3)Å b=28.131(3)Å c=11.1101(10)Å
α=90.00° β=98.696(2)° γ=90.00°
Erlotinib hemioxalate
2(C22H24N3O4),C2O42
Acta Crystallographica Section C (2010) 66, 1 o33-o38
a=7.6285(8)Å b=10.2252(10)Å c=14.6525(14)Å
α=86.076(2)° β=84.925(2)° γ=70.559(2)°
Granisetron
C18H24N4O
Acta Crystallographica Section C (2010) 66, 2 m35-m39
a=13.7930(12)Å b=13.5544(12)Å c=17.9574(16)Å
α=90.00° β=90.00° γ=90.00°
Erlotinib monohydrate
C22H23N3O4,H2O
Acta Crystallographica Section C (2010) 66, 1 o33-o38
a=9.0227(10)Å b=10.4548(11)Å c=13.2014(14)Å
α=98.705(2)° β=108.738(2)° γ=111.873(2)°
Erlotinib fumaric acid hemisolvate dihydrate
C22H23N3O4,0.5(C4H4O4),2(H2O)
Acta Crystallographica Section C (2010) 66, 1 o33-o38
a=7.967(2)Å b=13.248(4)Å c=13.745(4)Å
α=108.916(5)° β=106.673(5)° γ=101.909(5)°
Diaqua[1-methyl-<i>N</i>-(9-methyl-9-azoniabicyclo[3.3.1]nonan-7-yl)indazole- 3-carboxamide]cobalt(II) tetrachloride dodecahydrate
C36H54CoN8O44,4(Cl),12(H2O)
Acta Crystallographica Section C (2010) 66, 2 m35-m39
a=9.6311(9)Å b=9.9794(9)Å c=16.0133(14)Å
α=92.6110(10)° β=103.4490(10)° γ=118.0370(10)°
4-(4-{3-[4-chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)- <i>N</i>-methylpyridine-2-carboxamide
C21H16ClF3N4O3
Acta Crystallographica Section C (2011) 67, 1 o29-o32
a=8.1587(16)Å b=9.8055(19)Å c=27.758(5)Å
α=90.00° β=94.358(3)° γ=90.00°
4-(4-{3-[4-chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-2-(<i>N</i>- methylcarbamoyl)pyridinium 4-methylbenzenesulfonate
C21H17ClF3N4O3,C7H7O3S
Acta Crystallographica Section C (2011) 67, 1 o29-o32
a=21.276(4)Å b=9.1160(17)Å c=16.077(3)Å
α=90.00° β=108.143(3)° γ=90.00°
(2<i>R</i>,3<i>S</i>)-3-(3-hydroxyphenyl)- <i>N</i>,<i>N</i>,2-trimethylpentan-1-aminium chloride
C14H24NO,Cl
Acta Crystallographica Section C (2011) 67, 2 o71-o76
a=8.8218(6)Å b=12.1304(8)Å c=14.0031(9)Å
α=90.00° β=90.00° γ=90.00°
(2<i>S</i>,3<i>R</i>)-3-(3-hydroxyphenyl)- <i>N</i>,<i>N</i>,2-trimethylpentan-1-aminium chloride
C14H24NO,Cl
Acta Crystallographica Section C (2011) 67, 2 o71-o76
a=8.8101(6)Å b=12.1094(8)Å c=13.9784(9)Å
α=90.00° β=90.00° γ=90.00°
(2<i>S</i>,3<i>S</i>)-3-(3-hydroxyphenyl)- <i>N</i>,<i>N</i>,2-trimethylpentan-1-aminium chloride
C14H24NO,Cl
Acta Crystallographica Section C (2011) 67, 2 o71-o76
a=7.160(3)Å b=11.688(5)Å c=17.526(8)Å
α=90.00° β=94.570(7)° γ=90.00°
Cytosinium zoledronate trihydrate
C4H6N3O,C5H9N2O7P2,3(H2O)
Acta Crystallographica Section C (2011) 67, 3 o115-o119
a=6.7292(16)Å b=6.8032(16)Å c=19.193(5)Å
α=89.875(4)° β=86.747(5)° γ=84.726(4)°
Bis(adeninium) zoldronate tetrahydrate
2(C5H6N5),C5H8N2O7P22,4(H2O)
Acta Crystallographica Section C (2014) 70, 1 67-74
a=7.2128(7)Å b=17.7448(17)Å c=19.3945(18)Å
α=90.00° β=93.999(2)° γ=90.00°
Bis(adeninium) zoldronate hexahydrate
2(C5H6N5),C5H8N2O7P22,6(H2O)
Acta Crystallographica Section C (2014) 70, 1 67-74
a=7.2742(6)Å b=10.7987(9)Å c=17.6202(15)Å
α=102.3800(10)° β=94.2540(10)° γ=93.2230(10)°
4<i>H</i>-1,2,4-Triazolo[3,4-<i>c</i>][1,4]benzothiazin-1(2<i>H</i>)-one
C9H7N3OS
Acta Crystallographica Section C (2012) 68, 11 o475-o480
a=14.6307(11)Å b=8.5718(7)Å c=28.083(2)Å
α=90.00° β=90.00° γ=90.00°
2-(2-Oxo-2-phenylethyl)-4<i>H</i>-1,2,4-triazolo[3,4- <i>c</i>][1,4]benzothiazin-1(2<i>H</i>)-one
C17H13N3O2S
Acta Crystallographica Section C (2012) 68, 11 o475-o480
a=11.6248(18)Å b=14.920(2)Å c=8.5909(13)Å
α=90.00° β=102.564(3)° γ=90.00°
Ethyl 3-oxo-2-(1-oxo-1<i>H</i>,4<i>H</i>-1,2,4-triazolo[3,4- <i>c</i>][1,4]benzothiazin-2-yl)-3-phenylpropanoate
C20H17N3O4S
Acta Crystallographica Section C (2012) 68, 11 o475-o480
a=13.6533(14)Å b=12.7279(13)Å c=22.2927(19)Å
α=90.00° β=100.601(3)° γ=90.00°
6-methyl-5-(N-methylcarbamoyl)-4-phenyl-1,2,3,4-dihydropyrimidine-2-thione monohydrate
C13H15N3OS,H2O
Acta Crystallographica Section C (2005) 61, 1 o41-o44
a=5.0116(3)Å b=8.9507(6)Å c=16.0882(11)Å
α=86.0950(10)° β=84.8410(10)° γ=78.2410(10)°
4-(4-chlorophenyl)-6-methyl-5-(N-methylcarbamoyl)-1,2,3,4-dihydropyrimidine- 2-thione monohydrate
C13H14ClN3OS,H2O
Acta Crystallographica Section C (2005) 61, 1 o41-o44
a=4.8853(3)Å b=9.7093(7)Å c=16.0343(11)Å
α=79.5060(10)° β=84.7920(10)° γ=82.8340(10)°
8-chloro-9-fluoro-5-phenyl-3,4,4a,5,6,10b-hexahydro-2H-pyrano[3,2-c]quinoline
C18H17ClFNO
Acta Crystallographica Section C (2005) 61, 5 o267-o269
a=10.5399(7)Å b=11.2005(7)Å c=13.4950(9)Å
α=82.5970(10)° β=83.8900(10)° γ=80.8840(10)°
10-chloro-9-fluoro-5-phenyl-3,4,4a,5,6,10b-hexahydro-2H-pyrano[3,2-c]quinoline
C18H17ClFNO
Acta Crystallographica Section C (2005) 61, 5 o267-o269
a=8.3032(8)Å b=10.5190(11)Å c=18.1165(18)Å
α=104.234(2)° β=92.309(2)° γ=91.783(2)°
4-[2-(dipropylamino)ethyl]-2,3-dihydro-1H-indol-2-ol hydrochloride
C16H25N2O,Cl
Acta Crystallographica Section C (2006) 62, 5 o265-o267
a=7.5388(11)Å b=8.9545(13)Å c=12.1647(18)Å
α=80.005(2)° β=85.968(2)° γ=83.504(2)°
Adeninium phenylacetate phenylacetic acid hydrate
C5H6N5,C8H7O2,C8H8O2,H2O
Acta Crystallographica Section C (2007) 63, 7 o415-o418
a=4.7805(10)Å b=10.303(2)Å c=21.678(5)Å
α=88.886(4)° β=87.595(3)° γ=83.239(4)°
Adeninium succinate hydrate
C5H6N5,C4H3O4,H2O
Acta Crystallographica Section C (2007) 63, 7 o415-o418
a=9.539(3)Å b=17.149(6)Å c=7.450(3)Å
α=90.00° β=100.503(5)° γ=90.00°
(<i>S</i>)-4-{3-[2-(dimethylamino)ethyl]-1<i>H</i>-indol-5- ylmethyl}oxazolidin-2-one benzene solvate
C16H21N3O2,C6H6
Acta Crystallographica Section C (2007) 63, 7 o437-o440
a=8.6938(5)Å b=12.1331(7)Å c=19.5321(12)Å
α=90.00° β=90.00° γ=90.00°
(<i>S</i>)-4-{3-[2-(dimethylamino)ethyl]-1<i>H</i>-indol-5- ylmethyl}oxazolidin-2-one phenol solvate
C16H21N3O2,C6H6O
Acta Crystallographica Section C (2007) 63, 7 o437-o440
a=8.7618(13)Å b=19.506(3)Å c=12.1767(18)Å
α=90.00° β=91.399(2)° γ=90.00°
(2<i>S</i>,4<i>R</i>)-2-(<i>N</i>-{(1<i>S</i>,2<i>S</i>)-2-chloro-1- [(3<i>R</i>,4<i>S</i>,5<i>R</i>,6<i>R</i>)-3,4,5-trihydroxy-6- (methylsulfanyl)perhydropyran-2-yl]propyl}aminocarbonyl)-4-propylpyrrolidinium chloride monohydrate
C18H34ClN2O5S,Cl,H2O
Acta Crystallographica Section C (2010) 66, 2 o97-o100
a=9.4669(6)Å b=9.9255(6)Å c=13.4949(8)Å
α=90.00° β=104.6010(10)° γ=90.00°
(2<i>S</i>,4<i>R</i>)-2-(<i>N</i>-{(1<i>S</i>,2<i>S</i>)-2-chloro-1- [(3<i>R</i>,4<i>S</i>,5<i>R</i>,6<i>R</i>)-3,4,5-trihydroxy-6- (methylsulfanyl)perhydropyran-2-yl]propyl}aminocarbonyl)-4-propylpyrrolidinium chloride monohydrate ethanol solvate
C18H34ClN2O5S,Cl,H2O,C2H6O
Acta Crystallographica Section C (2010) 66, 2 o97-o100
a=9.9630(16)Å b=10.6998(17)Å c=26.324(4)Å
α=90.00° β=90.00° γ=90.00°
Frovatriptan succinate monohydrate
C14H18N3O,C4H5O4,H2O
Acta Crystallographica Section C (2013) 69, 4 428-435
a=10.6206(6)Å b=7.9939(5)Å c=22.3916(13)Å
α=90.00° β=92.8840(10)° γ=90.00°
Frovatriptan acetate
C14H18N3O,C2H3O2
Acta Crystallographica Section C (2013) 69, 4 428-435
a=11.2397(8)Å b=16.7124(13)Å c=8.6528(6)Å
α=90.00° β=96.1500(10)° γ=90.00°
Eletriptan hydrobromide monohydrate
C22H27N2O2S,Br,H2O
Acta Crystallographica Section C (2008) 64, 12 o653-o656
a=9.4019(6)Å b=13.4089(8)Å c=18.0173(11)Å
α=90.00° β=90.00° γ=90.00°
Naratriptan hydrochloride
C17H26N3O2S,Cl
Acta Crystallographica Section C (2008) 64, 12 o653-o656
a=6.1914(5)Å b=12.2298(10)Å c=12.9948(11)Å
α=78.3480(10)° β=76.3380(10)° γ=86.0330(10)°
Lapatinb monotosylate
C29H27ClFN4O4S,C7H7O3S
Acta Crystallographica Section C (2013) 69, 12 1516-1523
a=5.7828(4)Å b=20.7395(14)Å c=29.4867(19)Å
α=90.00° β=90.00° γ=90.00°
Lapatinib ditosylate
C29H28ClFN4O4S2,2(C7H7O3S)
Acta Crystallographica Section C (2013) 69, 12 1516-1523
a=9.2122(6)Å b=13.2387(9)Å c=18.3758(12)Å
α=95.3870(10)° β=92.4630(10)° γ=100.3590(10)°
Lamotrigine
C9H7Cl2N5
Acta Crystallographica Section C (2009) 65, 9 o460-o464
a=19.136(3)Å b=8.6409(12)Å c=13.5549(18)Å
α=90.00° β=109.172(2)° γ=90.00°
Lamotriginium chloride
C9H8Cl2N5,Cl
Acta Crystallographica Section C (2009) 65, 9 o460-o464
a=16.664(5)Å b=5.5139(17)Å c=13.392(4)Å
α=90.00° β=102.588(5)° γ=90.00°
Lamotriginium nitrate
C9H8Cl2N5,NO3
Acta Crystallographica Section C (2009) 65, 9 o460-o464
a=7.1356(9)Å b=13.3711(17)Å c=14.0294(18)Å
α=88.285(2)° β=85.502(2)° γ=75.516(2)°
Safinamide
C17H19FN2O2
Acta Crystallographica Section C (2010) 66, 6 o317-o320
a=5.1127(5)Å b=17.8516(16)Å c=17.87460(10)Å
α=90.00° β=90.00° γ=90.00°
Safinamide
C17H19FN2O2
Acta Crystallographica Section C (2010) 66, 6 o317-o320
a=6.6297(9)Å b=8.1015(12)Å c=29.268(4)Å
α=90.00° β=90.00° γ=90.00°
(4S)-trans-4-ethylammonio-5,6-dihydro-6-methyl-4H-thieno[2,3-b]thiopyran- 2-sulfonamide 7,7-dioxide chloride
C10H17N2O4S3,Cl
Acta Crystallographica Section C (2007) 63, 2 o108-o110
a=8.1272(6)Å b=10.0646(8)Å c=18.2504(14)Å
α=90.00° β=90.00° γ=90.00°
Cytosinium nicotinate hydrate
C4H6N3O,C6H4NO2,H2O
Acta Crystallographica Section C (2010) 66, 8 o414-o417
a=7.5314(5)Å b=18.2710(12)Å c=8.4249(6)Å
α=90.00° β=104.3740(10)° γ=90.00°
Cytosinium isonicotinate cytosine dihydrate
C4H6N3O,C6H4NO2,C4H5N3O,2H2O
Acta Crystallographica Section C (2010) 66, 8 o414-o417
a=7.1852(8)Å b=7.3627(8)Å c=17.7387(18)Å
α=99.831(2)° β=92.928(2)° γ=107.862(2)°
Moxifloxacin hydrochloride
C21H25FN3O4,Cl,0.5H2O,0.5CH4O
Acta Crystallographica Section C (2006) 62, 8 o478-o482
a=6.828(2)Å b=20.929(6)Å c=15.357(5)Å
α=90.00° β=92.007(5)° γ=90.00°
5,3'-dihydroxy-3,6,7,4',5'-pentamethoxyflavone
C20H20O9
Acta Crystallographica Section C (2006) 62, 8 o495-o497
a=7.5629(5)Å b=15.2199(9)Å c=17.6543(11)Å
α=69.6210(10)° β=83.1450(10)° γ=77.7600(10)°
9-methyl-5-phenyl-3,4,4a,5,6,10b-hexahydro-2H-pyrano[3,2-c]quinoline
C19H21NO
Acta Crystallographica Section C (2006) 62, 9 o574-o576
a=8.2596(7)Å b=10.0084(9)Å c=10.1134(9)Å
α=66.4350(10)° β=81.927(2)° γ=77.1410(10)°
(+-)-2-(4-methoxyphenyl)-1-phenethyl-2,3-dihydroquinazolin-4(1H)-one
C23H22N2O2
Acta Crystallographica Section C (2008) 64, 2 o80-o83
a=6.7224(15)Å b=10.326(2)Å c=14.694(3)Å
α=109.331(4)° β=100.233(4)° γ=90.803(4)°
(+-)-2-(1,3-benzodioxol-5-yl))-1-phenethyl-2,3-dihydroquinazolin-4(1H)-one
C23H20N2O3
Acta Crystallographica Section C (2008) 64, 2 o80-o83
a=29.840(5)Å b=6.6467(10)Å c=20.587(3)Å
α=90.00° β=109.529(2)° γ=90.00°
Almotriptan
C17H25N3O2S
Acta Crystallographica Section C (2008) 64, 1 o15-o17
a=20.5023(17)Å b=7.6894(6)Å c=22.8470(19)Å
α=90.00° β=104.904(2)° γ=90.00°
Almotriptan Malate
C17H26N3O2S,C4H5O5
Acta Crystallographica Section C (2008) 64, 1 o15-o17
a=7.5542(7)Å b=9.3561(9)Å c=17.3608(17)Å
α=104.081(2)° β=101.121(2)° γ=92.681(2)°
Cytosinium succinate
C4H6N3O,C4H5O4
Acta Crystallographica Section C (2008) 64, 10 o566-o569
a=15.666(3)Å b=6.6959(9)Å c=18.726(3)Å
α=90.00° β=100.480(4)° γ=90.00°
Cytosinium 4-nitrobenzoate cytosine monohydrate
C4H6N3O,C7H4NO4,C4H5N3O,H2O
Acta Crystallographica Section C (2008) 64, 10 o566-o569
a=6.7154(14)Å b=7.4036(16)Å c=19.228(4)Å
α=85.525(4)° β=87.576(4)° γ=67.279(3)°
Xanthinium hydrogen sulfate hydrate
C5H5N4O2,HO4S,H2O
Acta Crystallographica Section C (2011) 67, 10 o382-o386
a=5.183(5)Å b=24.805(5)Å c=7.701(5)Å
α=90.00° β=103.510(5)° γ=90.00°
Xanthinium nitrate hydrate
C5H5N4O2,NO3,H2O
Acta Crystallographica Section C (2011) 67, 10 o382-o386
a=5.0416(7)Å b=7.4621(10)Å c=12.1396(16)Å
α=80.248(2)° β=80.800(2)° γ=75.657(2)°
Zolmitriptan hydrogen oxalate
C16H22N3O2,C2HO4
Acta Crystallographica Section C (2013) 69, 10 1186-1191
a=5.5944(4)Å b=17.9908(14)Å c=18.3844(15)Å
α=90.00° β=92.2200(10)° γ=90.00°
Zolmitriptan camphor sulfonate
C16H22N3O2,C10H15O4S
Acta Crystallographica Section C (2013) 69, 10 1186-1191
a=9.5992(15)Å b=16.361(3)Å c=16.927(2)Å
α=90.00° β=90.00° γ=90.00°
Lamotriginium 4-methylbenzoate <i>N</i>,<i>N</i>-dimethylformamide monosolvate
C9H7.41Cl2N5,C8H7.59O2,C3H7NO
Acta Crystallographica Section C (2013) 69, 10 1164-1169
a=9.3976(12)Å b=24.904(3)Å c=10.2105(14)Å
α=90.00° β=108.976(3)° γ=90.00°
Lamotriginium 4-iodobenzoate <i>N</i>,<i>N</i>-dimethylformamide monosolvate
C9H7.54Cl2N5,C7H4.46IO2,C3H7NO
Acta Crystallographica Section C (2013) 69, 10 1164-1169
a=9.7282(6)Å b=24.9148(16)Å c=10.0307(6)Å
α=90.00° β=108.6180(10)° γ=90.00°
Lamotriginium 3,5-dinitro-2-hydroxybenzoate <i>N</i>,<i>N</i>-dimethylformamide monosolvate
C9H8Cl2N5,C7H3N2O7,C3H7NO
Acta Crystallographica Section C (2013) 69, 10 1164-1169
a=10.0227(5)Å b=10.5507(5)Å c=12.5359(6)Å
α=81.8580(10)° β=71.8880(10)° γ=70.0090(10)°